We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Illumina Inc | NASDAQ:ILMN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.60 | 0.56% | 108.21 | 108.19 | 108.26 | 109.69 | 106.00 | 106.93 | 426,138 | 16:37:24 |
From May 2023 to May 2024
By Ben Glickman
Illumina is evaluating divestiture options for Grail after the European Commission ruled the gene-sequencing company had 12 months to sell the recently acquired business.
The San Diego-based company said Friday that it could explore a third-party sale or a capital markets transaction under the EC's order, which allows for flexibility in the structure of the divestiture. The company also may be able to extend the deadline to complete the divestiture by three additional months.
Illumina acquired the cancer-test developer Grail for $7.1 billion in 2021, but the deal was blocked last year by regulators over antitrust concerns.
Illumina said Friday that it still believed the EC did not have jurisdiction over its acquisition. The company has challenged the EC's jurisdiction in the European Court of Justice, and a decision in the case is pending.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 13, 2023 14:42 ET (18:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Illumina Chart |
1 Month Illumina Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
